Exact Mass: 367.1545

Exact Mass Matches: 367.1545

Found 158 metabolites which its exact mass value is equals to given mass value 367.1545, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Isatidine

Retrorsine N-oxide

C18H25NO7 (367.1631)


   

Tryptophyl-Tyrosine

2-{[2-amino-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino}-3-(4-hydroxyphenyl)propanoate

C20H21N3O4 (367.1532)


Tryptophyl-Tyrosine is a dipeptide composed of tryptophan and tyrosine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Casuarine 6-alpha-D-glucoside

3-(hydroxymethyl)-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexahydro-1H-pyrrolizine-1,2,7-triol

C14H25NO10 (367.1478)


Casuarine 6-alpha-D-glucoside is found in fruits. Casuarine 6-alpha-D-glucoside is an alkaloid from Eugenia jambolana (jambolan

   

Tyrosyl-Tryptophan

2-{[2-amino-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-(1H-indol-3-yl)propanoate

C20H21N3O4 (367.1532)


Tyrosyl-Tryptophan is a dipeptide composed of tyrosine and tryptophan. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

N-Acetyl-6-O-L-fucosyl-D-glucosamine

N-[(2R,3R,4S)-3,4,5-Trihydroxy-1-oxo-6-{[(3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-2-yl]ethanimidate

C14H25NO10 (367.1478)


N-Acetyl-6-O-L-fucosyl-D-glucosamine is an oligosaccharin obtained from human milk (Fiziologiya i Biokhimiya Kulturnykh Rastenii (2002), 34(1), 52-57) [HMDB] N-Acetyl-6-O-L-fucosyl-D-glucosamine is an oligosaccharin obtained from human milk (Fiziologiya i Biokhimiya Kulturnykh Rastenii (2002), 34(1), 52-57).

   

2-Acetamido-2-deoxy-6-O-a-L-fucopyranosyl-D-glucose

N-{3,4,5-trihydroxy-1-oxo-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]hexan-2-yl}ethanimidate

C14H25NO10 (367.1478)


2-Acetamido-2-deoxy-6-O-a-L-fucopyranosyl-D-glucose is an oligosaccharide isolated from the urine of patients with fucosidosis (Fucosidosis is an autosomal recessive lysosomal storage disease caused by defective alpha-L-fucosidase with accumulation of fucose in the tissues. Different phenotypes include clinical features such as neurologic deterioration, growth retardation, visceromegaly, and seizures in a severe early form; coarse facial features, angiokeratoma corporis diffusum, spasticity and delayed psychomotor development in a longer surviving form; and an unusual spondylometaphyseoepiphyseal dysplasia in yet another form. OMIM 230000). (PMID 728478) [HMDB] 2-Acetamido-2-deoxy-6-O-a-L-fucopyranosyl-D-glucose is an oligosaccharide isolated from the urine of patients with fucosidosis (Fucosidosis is an autosomal recessive lysosomal storage disease caused by defective alpha-L-fucosidase with accumulation of fucose in the tissues. Different phenotypes include clinical features such as neurologic deterioration, growth retardation, visceromegaly, and seizures in a severe early form; coarse facial features, angiokeratoma corporis diffusum, spasticity and delayed psychomotor development in a longer surviving form; and an unusual spondylometaphyseoepiphyseal dysplasia in yet another form. OMIM 230000). (PMID 728478).

   

3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose

N-[(2R,3R,4R,5R)-4,5,6-Trihydroxy-1-oxo-3-{[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-2-yl]ethanimidate

C14H25NO10 (367.1478)


3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose is an oligosaccharide is a fucosylated oligosaccharide specific to human, and in milk forms part of the innate immune system. (PMID: 1579031). It is present in a number of proteins, such as human transferrin. Hepatocytes contain a receptor that binds glycoproteins specifically through the fucose in alpha13 linkage to N-acetylglucosamine. (PMID: 276862). It is also present in some forms of human kidney enzyme alpha-L-fucosidase (EC 3.2.1.51) (PMID: 7215135). 3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose is an oligosaccharide is a fucosylated oligosaccharide specific to human, and in milk forms part of the innate immune system. (PMID: 1579031)

   

Desmethylazelastine

2-(azepan-4-yl)-4-[(4-chlorophenyl)methyl]-1,2-dihydrophthalazin-1-one

C21H22ClN3O (367.1451)


Desmethylazelastine is a metabolite of Azelastine. Azelastine, an antiallergy and antiasthmatic drug, has been reported to be mainly N-demethylated to desmethylazelastine in humans. Azelastine N-demethylation in humans liver microsomes is catalyzed mainly by CYP3A4 and CYP2D6, and CYP1A2 to a small extent (in average, 76.6, 21.8, and 3.9\\%, respectively. (PMID: 10570018)

   

Fradafiban

2-{5-[({4-carbamimidoyl-[1,1-biphenyl]-4-yl}oxy)methyl]-2-oxopyrrolidin-3-yl}acetic acid

C20H21N3O4 (367.1532)


   

Pyrazoloacridine

(3-{4-methoxy-10-nitro-8,14,15-triazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-14-yl}propyl)dimethylamine

C19H21N5O3 (367.1644)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents D000970 - Antineoplastic Agents

   

(2S)-2-Amino-3-[4-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]oxyphenyl]propanoic acid

(2S)-2-Amino-3-[4-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]oxyphenyl]propanoic acid

C20H21N3O4 (367.1532)


   

O-Methylsakambullin

O-Methylsakambullin

C18H25NO5S (367.1453)


   

Jacobine N-oxide

Jacobine N-oxide

C18H25NO7 (367.1631)


A pyrrolizine alkaloid that is jacobine in which the tertiary amino function has been oxidised to the corresponding N-oxide. CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2257 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 179 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 169 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 159 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 149 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 139 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 129 INTERNAL_ID 129; CONFIDENCE Reference Standard (Level 1) CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 119 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 109

   
   

beta-D-GlcpNAc-(1-3)-L-Rha

beta-D-GlcpNAc-(1-3)-L-Rha

C14H25NO10 (367.1478)


   

(E)-3-(methylsulfonyl)-propenoic acid 4-(3-methyl-2-butenyloxy)-3-methoxyphenethyl amide|O-methylsakambullin

(E)-3-(methylsulfonyl)-propenoic acid 4-(3-methyl-2-butenyloxy)-3-methoxyphenethyl amide|O-methylsakambullin

C18H25NO5S (367.1453)


   

3alpha-(3,4,5-trimethoxybenzoyloxy)tropan-6beta,7beta-diol|3alpha-(3,4,5-trimethoxybenzoyloxy)tropan-6beta,7beta-diol|Tropane-3alpha,6beta,7beta-triol 3-(3,4,5-trimethoxybenzoate)

3alpha-(3,4,5-trimethoxybenzoyloxy)tropan-6beta,7beta-diol|3alpha-(3,4,5-trimethoxybenzoyloxy)tropan-6beta,7beta-diol|Tropane-3alpha,6beta,7beta-triol 3-(3,4,5-trimethoxybenzoate)

C18H25NO7 (367.1631)


   
   
   
   
   
   
   
   
   
   
   
   

Isatidine

[1,6]Dioxacyclododecino[2,3,4-gh]pyrrolizine-2,7-dione, 3-ethylidene-3,4,5,6,9,11,13,14,14a,14b-decahydro-6-hydroxy-6-(hydroxymethyl)-5-methyl-, 12-oxide, (3Z,5R,6S,14aR,14bR)-; Isatidine (6CI,7CI); Retrorsine, N-oxide (8CI); Senecionan-11,16-dione, 12,18-dihydroxy-, 4-oxide; Retrorsine oxide

C18H25NO7 (367.1631)


Isatidine is a citraconoyl group.

   

RET-NO

(1R,4Z,6S,7S,17R)-4-Ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-14-oxido-2,9-dioxa-14-azoniatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

C18H25NO7 (367.1631)


Usaramine N-oxide, a alkaloid isolated from Crotalaria pallida, possesses anti-inflammatory activities[1].

   

Jacobine N-oxide

(1R,3S,6R,7R,17R)-7-hydroxy-3,6,7-trimethyl-14-oxidospiro[2,9-dioxa-14-azoniatricyclo[9.5.1.014,17]heptadec-11-ene-4,2-oxirane]-3,8-dione

C18H25NO7 (367.1631)


   

Retrorsine N-oxide

Retrorsine N-oxide

C18H25NO7 (367.1631)


CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2284

   

Demethylazelastine

Demethylazelastine

C21H22ClN3O (367.1451)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

N-Acetyl-6-O-L-fucosyl-D-glucosamine

2-(acetylamino)-2-Deoxy-6-O-(6-deoxy-L-galactopyranosyl)-D-glucose

C14H25NO10 (367.1478)


   

2-Acetamido-2-deoxy-6-O-a-L-fucopyranosyl-D-glucose

2-(acetylamino)-2-Deoxy-6-O-(6-deoxy-alpha-L-galactopyranosyl)-delta-glucose

C14H25NO10 (367.1478)


   

-O-Fucopyranosyl-2-acetamido-2-deoxyglucopyranose

2-(acetylamino)-2-Deoxy-3-O-(6-deoxy-alpha-L-galactopyranosyl)- D-glucose

C14H25NO10 (367.1478)


   

TRP-Tyr

2-[2-amino-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C20H21N3O4 (367.1532)


A dipeptide formed from L-tryptophan and L-tyrosine residues.

   

Tyr-TRP

2-[2-amino-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C20H21N3O4 (367.1532)


A dipeptide formed from L-tyrosine and L-tryptophan residues.

   

Casuarine 6-a-D-glucoside

3-(hydroxymethyl)-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexahydro-1H-pyrrolizine-1,2,7-triol

C14H25NO10 (367.1478)


   
   

2-(3,4-dimethoxyphenyl)-N-[(2,3-dimethoxyphenyl)methyl]ethanamine,hydrochloride

2-(3,4-dimethoxyphenyl)-N-[(2,3-dimethoxyphenyl)methyl]ethanamine,hydrochloride

C19H26ClNO4 (367.155)


   

N2-ibu-2-OMe-rG

N2-ibu-2-OMe-rG

C15H21N5O6 (367.1492)


N2-Isobutyryl-2'-O-methylguanosine (N2-IBU-2'-OME-RG) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].

   

(1R,2S,3R,4R,5R)-4-Azido-2,3-bis(benzyloxy)-6,8-dioxabicyclo[3.2. 1]octane (non-preferred name)

(1R,2S,3R,4R,5R)-4-Azido-2,3-bis(benzyloxy)-6,8-dioxabicyclo[3.2. 1]octane (non-preferred name)

C20H21N3O4 (367.1532)


   

4H,6H-Indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium, 5a,10b-dihydro-2-(2,4,6-trimethylphenyl)-, chloride , (5aS,10bR)

4H,6H-Indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium, 5a,10b-dihydro-2-(2,4,6-trimethylphenyl)-, chloride , (5aS,10bR)

C21H22ClN3O (367.1451)


   

N-(1-Boc-piperidin-4-ylidene)-4-methylbenzenesulfonohydrazide

N-(1-Boc-piperidin-4-ylidene)-4-methylbenzenesulfonohydrazide

C17H25N3O4S (367.1566)


   

2-ACETAMIDO-2-DEOXY-3-O-(A-L-FUCOPYRANOSYL)-D-GLUCOPYRANOSE

2-ACETAMIDO-2-DEOXY-3-O-(ALPHA-L-FUCOPYRANOSYL)-D-GLUCOPYRANOSE

C14H25NO10 (367.1478)


   

Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]

Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]

C18H20F3N3O2 (367.1508)


   

2-[[5-(DIBUTYLAMINO)-2-THIENYL]METHYLENE]-1H-INDENE-1,3(2H)-DIONE

2-[[5-(DIBUTYLAMINO)-2-THIENYL]METHYLENE]-1H-INDENE-1,3(2H)-DIONE

C22H25NO2S (367.1606)


   

2-ACETAMIDO-2-DEOXY-6-O-(ALPHA-L-FUCOPYRANOSYL)-D-GLUCOPYRANOSE

2-ACETAMIDO-2-DEOXY-6-O-(ALPHA-L-FUCOPYRANOSYL)-D-GLUCOPYRANOSE

C14H25NO10 (367.1478)


   

2-Borono-4-(phenylmethoxy)-1H-indole-1-carboxylic acid 1-(1,1-dimethylethyl) ester

2-Borono-4-(phenylmethoxy)-1H-indole-1-carboxylic acid 1-(1,1-dimethylethyl) ester

C20H22BNO5 (367.1591)


   

5-Benzyloxy-1-Boc-indole-2-boronic acid

5-Benzyloxy-1-Boc-indole-2-boronic acid

C20H22BNO5 (367.1591)


   

6-Benzyloxy-1-Boc-indole-2-boronic acid

6-Benzyloxy-1-Boc-indole-2-boronic acid

C20H22BNO5 (367.1591)


   

2-Acetamido-2-deoxy-4-O-(a-L-fucopyranosyl)-D-glucopyranose

2-ACETAMIDO-2-DEOX-4-O-(ALPHA-L-FUCOPYRANOSYL)-D-GLUCOPYRANOSE

C14H25NO10 (367.1478)


   

Fradafiban

Fradafiban

C20H21N3O4 (367.1532)


C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent

   

Neocitrullamon

Neocitrullamon

C20H21N3O4 (367.1532)


N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AB - Hydantoin derivatives

   

Mirogabalin besylate

Mirogabalin besylate

C18H25NO5S (367.1453)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

   

[3H]dehydroepiandrosterone sulfate

[3H]dehydroepiandrosterone sulfate

C19H27O5S- (367.1579)


COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Tyrosyl-Tryptophan

Tyrosyl-Tryptophan

C20H21N3O4 (367.1532)


   

2-(acetylamino)-2-deoxy-3-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-glucopyranose

2-(acetylamino)-2-deoxy-3-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-glucopyranose

C14H25NO10 (367.1478)


   

alpha-L-fucosyl-(1->4)-N-acetyl-beta-D-glucosamine

alpha-L-fucosyl-(1->4)-N-acetyl-beta-D-glucosamine

C14H25NO10 (367.1478)


An amino disaccharide consisting of an alpha-L-fucosyl residue attached to N-acetyl-beta-Dglucosamine by a (1->4)-glycosidic linkage.

   

4-(3,4-Dimethoxyphenyl)-2-(1-piperidinyl)-6-(trifluoromethyl)pyrimidine

4-(3,4-Dimethoxyphenyl)-2-(1-piperidinyl)-6-(trifluoromethyl)pyrimidine

C18H20F3N3O2 (367.1508)


   

N-((2S,3R,4R,5S,6R)-2,4,5-Trihydroxy-6-((((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3-yl)acetamide

N-((2S,3R,4R,5S,6R)-2,4,5-Trihydroxy-6-((((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3-yl)acetamide

C14H25NO10 (367.1478)


   

N-((2R,3R,4R,5S,6R)-2,4,5-Trihydroxy-6-((((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3-yl)acetamide

N-((2R,3R,4R,5S,6R)-2,4,5-Trihydroxy-6-((((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3-yl)acetamide

C14H25NO10 (367.1478)


   

N-((2S,3R,4R,5S,6R)-2,4-Dihydroxy-6-(hydroxymethyl)-5-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-yl)acetamide

N-((2S,3R,4R,5S,6R)-2,4-Dihydroxy-6-(hydroxymethyl)-5-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-yl)acetamide

C14H25NO10 (367.1478)


   

[N-(2,4-Diaminopteridin-6-YL)-methyl]-dibenz[B,F]azepine

[N-(2,4-Diaminopteridin-6-YL)-methyl]-dibenz[B,F]azepine

C21H17N7 (367.1545)


D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists

   

2-[4-(4-Hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-2H-[1,2,4]triazine-3,5-dione

2-[4-(4-Hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-2H-[1,2,4]triazine-3,5-dione

C20H21N3O4 (367.1532)


   

Testosterone-17beta-sulfate

Testosterone-17beta-sulfate

C19H27O5S- (367.1579)


   

3-hydroxy-5-methoxy-6-[(2E)-3-(4-methoxyphenyl)prop-2-enoyl]-2-(3-methylbut-2-en-1-yl)phenolate

3-hydroxy-5-methoxy-6-[(2E)-3-(4-methoxyphenyl)prop-2-enoyl]-2-(3-methylbut-2-en-1-yl)phenolate

C22H23O5- (367.1545)


   

(2S)-2-Amino-3-[4-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]oxyphenyl]propanoic acid

(2S)-2-Amino-3-[4-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]oxyphenyl]propanoic acid

C20H21N3O4 (367.1532)


   

N-cyclopentyl-4-(3,4-dimethoxyphenyl)-6-(trifluoromethyl)-2-pyrimidinamine

N-cyclopentyl-4-(3,4-dimethoxyphenyl)-6-(trifluoromethyl)-2-pyrimidinamine

C18H20F3N3O2 (367.1508)


   

2-[4-[2-(1-Cyclohexenyl)ethylsulfamoyl]-2-methylphenoxy]acetic acid methyl ester

2-[4-[2-(1-Cyclohexenyl)ethylsulfamoyl]-2-methylphenoxy]acetic acid methyl ester

C18H25NO5S (367.1453)


   

beta-D-GlcpNAc-(1->3)-alpha-L-Fucp

beta-D-GlcpNAc-(1->3)-alpha-L-Fucp

C14H25NO10 (367.1478)


   

N-[[3-chloro-4-(1-piperidinyl)anilino]-sulfanylidenemethyl]hexanamide

N-[[3-chloro-4-(1-piperidinyl)anilino]-sulfanylidenemethyl]hexanamide

C18H26ClN3OS (367.1485)


   

Fuc(b1-6)b-GlcNAc

Fuc(b1-6)b-GlcNAc

C14H25NO10 (367.1478)


   

Epitestosterone sulfate(1-)

Epitestosterone sulfate(1-)

C19H27O5S- (367.1579)


   

2-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-3,5-dimethoxy-6-(3-methylbut-2-en-1-yl)phenolate

2-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-3,5-dimethoxy-6-(3-methylbut-2-en-1-yl)phenolate

C22H23O5- (367.1545)


   

(3S)-N-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide

(3S)-N-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide

C20H21N3O4 (367.1532)


   

Usaramine N-oxide

Usaramine N-oxide

C18H25NO7 (367.1631)


A pyrrolizine alkaloid that is senecionane bearing two additional hydroxy substituents at positions 12 and 18, two additional oxo groups at positions 11 and 16 and an N-oxido substituent. Usaramine N-oxide, a alkaloid isolated from Crotalaria pallida, possesses anti-inflammatory activities[1].

   
   
   
   

alpha-L-Rha-(1->3)-beta-D-GlcNAc

alpha-L-Rha-(1->3)-beta-D-GlcNAc

C14H25NO10 (367.1478)


An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having an alpha-L-rhamnosyl residue attached at the 3-position.

   

beta-L-fucosyl-(1->3)-N-acetyl-beta-D-glucosamine

beta-L-fucosyl-(1->3)-N-acetyl-beta-D-glucosamine

C14H25NO10 (367.1478)


An amino disaccharide consisting of a beta-L-fucosyl residue attached to N-acetyl-beta-Dglucosamine by a (1->3)-glycosidic linkage.

   

4-O-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-alpha-D-rhamnopyranose

4-O-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-alpha-D-rhamnopyranose

C14H25NO10 (367.1478)


   

2-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-alpha-L-rhamnopyranose

2-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-alpha-L-rhamnopyranose

C14H25NO10 (367.1478)


   

2-[3-(1-piperidinyl)propoxy]-6H-benzo[b][1]benzothiepin-5-one

2-[3-(1-piperidinyl)propoxy]-6H-benzo[b][1]benzothiepin-5-one

C22H25NO2S (367.1606)


   

(3R,6R,14aR,14bR)-3,6-dihydroxy-3-[(1R)-1-hydroxyethyl]-6-methyl-5-methylidene-3,4,5,6,9,11,13,14,14a,14b-decahydro[1,6]dioxacyclododecino[2,3,4-gh]pyrrolizine-2,7-dione

(3R,6R,14aR,14bR)-3,6-dihydroxy-3-[(1R)-1-hydroxyethyl]-6-methyl-5-methylidene-3,4,5,6,9,11,13,14,14a,14b-decahydro[1,6]dioxacyclododecino[2,3,4-gh]pyrrolizine-2,7-dione

C18H25NO7 (367.1631)


   

N-[1-(2,4-difluorophenyl)-4,5,6,7-tetrahydroindazol-4-yl]-2-phenylacetamide

N-[1-(2,4-difluorophenyl)-4,5,6,7-tetrahydroindazol-4-yl]-2-phenylacetamide

C21H19F2N3O (367.1496)


   

2-(dimethylamino)-1-[(2S,3S)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone

2-(dimethylamino)-1-[(2S,3S)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone

C17H25N3O4S (367.1566)


   

(1R,5S)-N-(2-chlorophenyl)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide

(1R,5S)-N-(2-chlorophenyl)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide

C21H22ClN3O (367.1451)


   

2-(dimethylamino)-1-[(2S,3R)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone

2-(dimethylamino)-1-[(2S,3R)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone

C17H25N3O4S (367.1566)


   

2-(dimethylamino)-1-[(2R,3R)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone

2-(dimethylamino)-1-[(2R,3R)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone

C17H25N3O4S (367.1566)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

beta-D-GlcpNAc-(1->3)-alpha-L-Rhap

beta-D-GlcpNAc-(1->3)-alpha-L-Rhap

C14H25NO10 (367.1478)


An amino disaccharide consisting of alpha-L-rhamnose having an N-acetyl beta-D-glucosaminyl residue attached at the 3-position.

   

Fuc(b1-3)a-GlcNAc

2-ACETAMIDO-2-DEOXY-3-O-(A-L-FUCOPYRANOSYL)-D-GLUCOPYRANOSE

C14H25NO10 (367.1478)


   

18-Hydroxyjacobine

18-Hydroxyjacobine

C18H25NO7 (367.1631)


   

GlcNAc(b1-3)Fuc

GlcNAc(b1-3)Fuc

C14H25NO10 (367.1478)


   

Fuc(b1-6)a-GlcNAc

Fuc(b1-6)a-GlcNAc

C14H25NO10 (367.1478)


   

Fuc(a1-3)a-GlcNAc

Fuc(a1-3)a-GlcNAc

C14H25NO10 (367.1478)


   

GlcNAc(b1-3)b-Fuc

GlcNAc(b1-3)b-Fuc

C14H25NO10 (367.1478)


   

testosterone sulfate(1-)

testosterone sulfate(1-)

C19H27O5S (367.1579)


A steroid sulfate oxoanion that is the conjugate base of testosterone sulfate, obtained by deprotonation of the sulfo group; major species at pH 7.3.

   

Desmethylazelastine

Desmethylazelastine

C21H22ClN3O (367.1451)


   

3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose

3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose

C14H25NO10 (367.1478)


   

Casuarine 6-alpha-D-glucoside

Casuarine 6-alpha-D-glucoside

C14H25NO10 (367.1478)


   

dehydroepiandrosterone sulfate(1-)

dehydroepiandrosterone sulfate(1-)

C19H27O5S (367.1579)


The conjugate base of 3beta-hydroxyandrost-5-en-17-one 3-sulfate arising from deprotonation of the sulfate OH group; major species at pH 7.3.

   

dehydrojacoline

dehydrojacoline

C18H25NO7 (367.1631)


A pyrrolizine alkaloid that is jacoline in which the 5-methyl group has been replaced by methylene.

   

beta-D-GlcpNAc-(1->2)-alpha-L-Rhap

beta-D-GlcpNAc-(1->2)-alpha-L-Rhap

C14H25NO10 (367.1478)


An amino disaccharide consisting of alpha-L-rhamnose having an N-acetyl beta-D-glucosaminyl residue attached at the 2-position.

   

beta-D-GlcpNAc-(1->4)-alpha-D-Rhap

beta-D-GlcpNAc-(1->4)-alpha-D-Rhap

C14H25NO10 (367.1478)


An amino disaccharide consisting of an alpha-D-rhamnos residue having an N-acetyl-beta-D-glucosaminyl residue attached at the 4-position.

   

alpha-L-Fucp-(1->3)-D-GlcpNAc

alpha-L-Fucp-(1->3)-D-GlcpNAc

C14H25NO10 (367.1478)


An amino disaccharide consisting of N-acetyl-D-glucosamine having an alpha-L-fucosyl residue attached at the 3-position.

   

alpha-L-fucosyl-(1->3)-N-acetyl-beta-D-glucosamine

alpha-L-fucosyl-(1->3)-N-acetyl-beta-D-glucosamine

C14H25NO10 (367.1478)


An amino disaccharide consisting of an alpha-L-fucosyl residue attached to N-acetyl-beta-Dglucosamine by a (1->3)-glycosidic linkage.

   

n-[(2s,3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(2s,3r,4s,5r,6r)-4,5,6-trihydroxy-2-methyloxan-3-yl]oxy}oxan-3-yl]ethanimidic acid

n-[(2s,3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(2s,3r,4s,5r,6r)-4,5,6-trihydroxy-2-methyloxan-3-yl]oxy}oxan-3-yl]ethanimidic acid

C14H25NO10 (367.1478)


   

(1r,4e,6r,7s,14s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

(1r,4e,6r,7s,14s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

C18H25NO7 (367.1631)


   

6-hydroxy-4,5,6-trimethyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate

6-hydroxy-4,5,6-trimethyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate

C18H25NO7 (367.1631)


   

2-(6-aminopurin-9-yl)-5-({[3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxolan-3-ol

2-(6-aminopurin-9-yl)-5-({[3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxolan-3-ol

C15H21N5O6 (367.1492)


   

(2r,3r,5s)-2-(6-aminopurin-9-yl)-5-({[(2r,3r,5s)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxolan-3-ol

(2r,3r,5s)-2-(6-aminopurin-9-yl)-5-({[(2r,3r,5s)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxolan-3-ol

C15H21N5O6 (367.1492)


   

(1r,4r,5r,6r,16r)-6-hydroxy-4,5,6-trimethyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate

(1r,4r,5r,6r,16r)-6-hydroxy-4,5,6-trimethyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate

C18H25NO7 (367.1631)


   

(2s,4e)-4-[(2z)-2-{[(1s)-4-carbamimidamido-1-carboxybutyl]imino}ethylidene]-2,3-dihydro-1h-pyridine-2,6-dicarboxylic acid

(2s,4e)-4-[(2z)-2-{[(1s)-4-carbamimidamido-1-carboxybutyl]imino}ethylidene]-2,3-dihydro-1h-pyridine-2,6-dicarboxylic acid

C15H21N5O6 (367.1492)


   

7-hydroxy-3',6,7-trimethyl-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-ene-3,8,17-trione

7-hydroxy-3',6,7-trimethyl-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-ene-3,8,17-trione

C18H25NO7 (367.1631)


   

(1r,4e,6r,7s)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

(1r,4e,6r,7s)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

C18H25NO7 (367.1631)


   

n-[4,5-dihydroxy-6-(hydroxymethyl)-2-[(4,5,6-trihydroxy-2-methyloxan-3-yl)oxy]oxan-3-yl]ethanimidic acid

n-[4,5-dihydroxy-6-(hydroxymethyl)-2-[(4,5,6-trihydroxy-2-methyloxan-3-yl)oxy]oxan-3-yl]ethanimidic acid

C14H25NO10 (367.1478)


   

(1r,4z,6r,7s,14s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

(1r,4z,6r,7s,14s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

C18H25NO7 (367.1631)


   

3-methanesulfonyl-n-(2-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)prop-2-enimidic acid

3-methanesulfonyl-n-(2-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)prop-2-enimidic acid

C18H25NO5S (367.1453)


   

2,6,12-trihydroxy-10-(3-hydroxybutan-2-yl)-5-(1-hydroxyethyl)-4,11-dimethyl-7-oxa-4-azatricyclo[6.4.0.0²,⁶]dodeca-1(12),8,10-trien-3-one

2,6,12-trihydroxy-10-(3-hydroxybutan-2-yl)-5-(1-hydroxyethyl)-4,11-dimethyl-7-oxa-4-azatricyclo[6.4.0.0²,⁶]dodeca-1(12),8,10-trien-3-one

C18H25NO7 (367.1631)


   

(1r,3's,4s,6r,7r,11z)-7-hydroxy-3',6,7-trimethyl-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-ene-3,8,17-trione

(1r,3's,4s,6r,7r,11z)-7-hydroxy-3',6,7-trimethyl-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-ene-3,8,17-trione

C18H25NO7 (367.1631)


   

(1r,4z,7s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

(1r,4z,7s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

C18H25NO7 (367.1631)


   

(2e)-3-methanesulfonyl-n-(2-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)prop-2-enimidic acid

(2e)-3-methanesulfonyl-n-(2-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)prop-2-enimidic acid

C18H25NO5S (367.1453)


   

(2s,5s,6s)-2,6,12-trihydroxy-10-[(2s,3r)-3-hydroxybutan-2-yl]-5-[(1r)-1-hydroxyethyl]-4,11-dimethyl-7-oxa-4-azatricyclo[6.4.0.0²,⁶]dodeca-1(12),8,10-trien-3-one

(2s,5s,6s)-2,6,12-trihydroxy-10-[(2s,3r)-3-hydroxybutan-2-yl]-5-[(1r)-1-hydroxyethyl]-4,11-dimethyl-7-oxa-4-azatricyclo[6.4.0.0²,⁶]dodeca-1(12),8,10-trien-3-one

C18H25NO7 (367.1631)